Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036) Meeting Abstract
| Authors: | Chi, P.; Janku, F.; Heinrich, M.; Ganjoo, K.; Gelderblom, H.; Gordon, M.; Jones, R.; Razak, A.; Trent, J.; von Mehren, M.; Hu, S. M.; Su, Y.; Ruiz-Soto, R.; George, S. |
| Abstract Title: | Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036) |
| Meeting Title: | AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| Journal Title: | Molecular Cancer Therapeutics |
| Volume: | 18 |
| Issue: | 12 |
| ISSN: | 1535-7163 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-01-01 |
| Language: | English |
| ACCESSION: | WOS:000510047200318 |
| DOI: | 10.1158/1535-7163.Targ-19-c077 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: C077 -- Source: Wos |
